免疫检查点抑制剂在肝癌肝移植中的应用进展OACSTPCD
Application progress of immune checkpoint inhibitors in liver transplantation for liver cancer
免疫检查点抑制剂(ICIs)为肝癌的治疗掀开了新的篇章,已成为肝癌转化和辅助治疗的主要选择之一.ICIs目前已较为广泛地应用于肝癌肝移植术前的降期治疗,且在肝移植术后肝癌复发转移的治疗中也进行探索性应用.但由于ICIs可引发排斥反应的潜在风险,使得其在肝癌肝移植术前、术后的应用中还存在诸多疑惑与问题.本文综合分析近年国内外在此领域的相关研究报告,以期为ICIs在肝移植术前及术后合理、安全、有效的应用提供参考.
Immune checkpoint inhibitors(ICIs)has opened a new chapter in the treatment of liver cancer and has become one of the main options for liver cancer transformation and adjuvant therapy.At present,ICIs has been widely used in the down-staging treatment of liver cancer before liver transplantation,and some exploratory applications have also been made in the treatment of liver cancer recurrence and metastasis after liver transplantation.However,due to the potential risk of rejection reactions induced by ICIs,there are still many doubts and problems in the application of ICIs before and after liver transplantation for liver cancer.In this paper,research reports related to this field domestic and overseas in recent years are comprehensively analyzed,aiming at providing references for the reasonable,safe and effective application of ICIs before and after liver transplantation.
张全保;王正昕
复旦大学附属华山医院普外科肝脏移植中心,上海市 200040
临床医学
肝癌肝移植免疫检查点抑制剂综述
Liver cancerLiver transplantationImmune checkpoint inhibitorsReview
《广西医学》 2024 (003)
340-346 / 7
国家重点研发计划项目(2023YFC2505900);国家自然科学基金(82241225,81873874,82071797)
评论